IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation.
Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graft-derived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor leukocyte transfusion is not available.
Nagayama
H
H
Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Japan.
Takahashi
S
S
Takahashi
T
T
Ogami
K
K
Ikebuchi
K
K
Tojo
A
A
Tani
K
K
Asano
S
S
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007948:Leukemia, Monocytic, Acute / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D007376:Interleukin-2; D010455:Peptides; C041640:poly(lysyl-(leucyl-poly-alanine))